Altor has developed a unique proprietary technology for producing biologically active, soluble TCR molecules in a single-chain format. The resulting STAR™ molecules retain the ability of the TCR to specifically recognize novel targets on virus-infected or cancerous cells, including intracellular antigens that are not accessible to therapeutic antibodies. Altor has developed STAR™ fusions with cytokines and antibody-like STAR™ fusions which function as therapeutics. STAR™ fusions are ideally suited to deliver anti-cancer and anti-viral drugs, such as approved immunomodulatory cytokines, cytotoxic drugs, radioisotopes, and imaging agents, directly to diseased cells and tissues. Altor's drug development strategy is to employ the unique antigen recognition properties of the TCR to lower the therapeutic dosage of currently approved drugs and decrease their side effects while maintaining their efficacy. Altor will adopt the proven clinical path of these approved drugs for development of STAR™-based therapeutics to maximize their chances of success in the clinic.